Biolite, Inc.
Clinical trials sponsored by Biolite, Inc., explained in plain language.
-
New combo therapy targets Hard-to-Treat breast cancer
Disease control Not yet recruitingThis study tests a new oral drug, BLEX 404, combined with chemotherapy (docetaxel) in people with advanced triple negative breast cancer. The goal is to find a safe dose and see if the combination helps shrink tumors. About 44 women aged 20-70 will take part.
Phase: PHASE1, PHASE2 • Sponsor: BioLite, Inc. • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
New drug combo aims to cut infections in blood cancer patients
Disease control Not yet recruitingThis study tests a new oral liquid drug, BLEX 404, combined with a standard chemotherapy (azacitidine) in adults with certain types of bone marrow cancers (MDS and CMML). The goal is to find a safe dose and see if it can reduce serious infections. About 52 people aged 20 and olde…
Phase: PHASE2 • Sponsor: BioLite, Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for cancer patients battling depression: experimental drug PDC-1421 enters early trials
Symptom relief Not yet recruitingThis early-phase study tests an experimental drug called PDC-1421 to see if it is safe and can help relieve depression in people with cancer. About 12 adults with stage I-III cancer and moderate to severe depression will take the drug for up to 5 weeks. Researchers will measure m…
Phase: PHASE1, PHASE2 • Sponsor: BioLite, Inc. • Aim: Symptom relief
Last updated May 08, 2026 12:02 UTC